HAYWARD, CA, July 11, 2000 - Sepragen Corporation (OTC BB:
SPGNU, SPGNA, SPGNW) a provider of patented technology and equipment for purification needs in the
nutritional and biotech industries, today announced the appointment of K.
Charles Janac to its Board of Directors. Mr. Janac is a 13D shareholder of Sepragen’s common stock.
Vinit Saxena, Chairman and CEO of Sepragen Corporation stated “Charlie Janac is a
dynamic builder of businesses with a proven track record in Silicon Valley.” He added, “His experience as an executive
and a strategist and his entrepreneurial spirit are greatly welcomed on the
Sepragen Board.”
Mr.
Janac started his career as a polymer chemist with the Exxon Chemical Company. He
was a co-founder of Cadence
Design Systems (NYSE:CDN) helping to build it into one of the top ten software
companies in the world. Following
Cadence Design Systems, he was the President of High Level Design Systems. He then formed Smart Machines, which he
recently sold to Brooks Automation (NASDAQ:BRKS) where he is responsible for
the atmospheric automation equipment business used in semiconductor and disk
drive manufacturing. Mr. Janac holds a
BS and MS degree in Organic Chemistry from Tufts University and an MBA from
Stanford Graduate School of Business.
“I am pleased to be joining the board of Sepragen Corporation,” said Mr.
Janac, he
added, “Sepragen is one of the most meaningful companies I know in terms of
positive impact on society. “It is a
technology leader in enabling pharmaceuticals and neutraceuticals reach volume
production”.
Sepragen Corporation develops and markets technology along with equipment and supplies
for process chromatography applications. Sepragen has developed a number of patented
applications that provide large market opportunities in the food and beverage industry,
including debittering citrus juices, extracting isoflavone (plant estrogen) from soy, as
well as extracting proteins from whey. The company holds over 14 issued patents relating
to its core technology. As of December 31, 1999, Sepragen had 5,412,562 common shares issued.
